Extensive lymph node surgery may not be necessary for some patients with melanoma

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

Pembrolizumab for head and neck cancer

Genomic marker predicts anti-PD-1 response in several cancers

Nivolumab extends survival for NSCLC

Promising results for nivolumab in advanced liver cancer

Nivolumab extends survival for patients with the most common lung cancer